Namratha Udupa M S, Babu K Govind, Suresh Babu M C, Lakshmaiah K C, Lokanatha D, Jacob A Linu, Lokesh K N, Rajeev L K, Rudresh A H, Devi Lakshmi
Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India.
Department of Pathology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India.
J Cancer Res Ther. 2020 Jan-Mar;16(1):18-22. doi: 10.4103/jcrt.JCRT_1162_16.
Acute myeloid leukemia (AML) in adults has poor prognosis. The epidemiologic profile of patients varies greatly in different geographic locations and so do the cytogenetic abnormalities and the FAB subtype of the AML. We intended to study the clinical profile, cytogenetics, and outcomes with standard of care treatment on our population in India.
This was a retrospective study with systematic review of 203 case records. Primary objectives were to know the demographic profile of AML, prevalence of various FAB subtypes, cytogenetic abnormalities, and treatment outcomes at our center, which is a referral center of oncology. Two treatment outcomes considered in study for patients of AML were achievement of remission status of the bone marrow postintensive induction chemotherapy and sustenance of the remission for 6 months, once remission is achieved. Secondary objective was to study these outcomes in non-M3 AML in relation to cytogenetics.
Median age was 39 years. The most common FAB subtype observed was AML M2. About 65.6% patients achieved complete remission (CR), and 42.4% patients could sustain it for next 6 months. Cytogenetics correlated with prognosis but not age.
Our population differs from the Western population regarding lower age, lower prevalence of adverse cytogenetics, and higher prevalence of favorable cytogenetic abnormalities. Cytogenetics had a good correlation with CR rates after chemotherapy as well as its sustenance.
成人急性髓系白血病（AML）预后较差。不同地理位置的患者流行病学特征差异很大，AML的细胞遗传学异常和FAB亚型也是如此。我们旨在研究印度人群中AML的临床特征、细胞遗传学及标准治疗的疗效。
这是一项对203例病例记录进行系统回顾的回顾性研究。主要目的是了解我们这个肿瘤转诊中心AML患者的人口统计学特征、各种FAB亚型的患病率、细胞遗传学异常情况及治疗效果。本研究中考虑的AML患者的两个治疗效果指标是强化诱导化疗后骨髓缓解状态的达成情况，以及缓解一旦实现后缓解状态维持6个月的情况。次要目的是研究非M3型AML中这些效果与细胞遗传学的关系。
中位年龄为39岁。观察到的最常见FAB亚型是AML M2。约65.6%的患者实现了完全缓解（CR），42.4%的患者能够在接下来的6个月内维持缓解状态。细胞遗传学与预后相关，但与年龄无关。
我们的人群在年龄较低、不良细胞遗传学患病率较低以及有利细胞遗传学异常患病率较高方面与西方人群不同。细胞遗传学与化疗后的CR率及其维持情况有良好的相关性。
